

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	Kind Attn.: Famroze Pochara Asst. Vice President
Date: March 9, 2016	
Re.: Press Release.	


Dear Sir / Madam,

We enclose herewith a copy of press release dated March 9, 2016 under the title **“Zydus receives tentative approval from the USFDA for Clofarabine Injection”**. The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For **Cadila Healthcare Limited**



Upen H. Shah
Company Secretary

Encl.: As above.

Zydus receives tentative approval from the USFDA for Clofarabine Injection

Ahmedabad, 09 March 2016

Zydus Cadila has received the tentative approval from the USFDA to market Clofarabine Injection 20mg/20ml vials.

The group now has more than 100 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04.
